Matt Tabas has extensive experience handling clients’ most complex antitrust issues. His practice focuses on government reviews of mergers and acquisitions, antitrust litigation, civil government investigations, and antitrust counseling. In particular, he has represented clients in all phases of merger clearance, before the US Department of Justice’s Antitrust Division, the Federal Trade Commission (FTC), state antitrust enforcement authorities, as well as before federal courts in litigated challenges by the government. He also frequently represents clients in high-stakes civil antitrust litigation.
Mr. Tabas regularly represents clients in a wide range of industries, including healthcare, life sciences, medical devices, technology, media and entertainment, telecommunications, semiconductors, consumer products, food, and retail.
Prior to joining the firm, Mr. Tabas served as a counsel to the director in the FTC's Bureau of Competition where he advised two Bureau of Competition Directors on antitrust issues affecting the healthcare, life sciences, technology, and chemical industries. Mr. Tabas also worked as an attorney in the Mergers IV Division of the FTC, investigating and analyzing combinations in the retail, healthcare, and funeral home industries. Among other assignments, he led investigations into the mergers of healthcare providers and played an integral role in the trial teams that successfully challenged several high profile mergers. While at the FTC, Mr. Tabas also participated in a staff exchange with Canada's Competition Bureau, where he worked as a Competition Law Officer in the Competition Bureau's Mergers Branch.
- Bristol-Myers Squibb in its $4.1 billion acquisition of Turning Point Therapeutics.
- Pfizer in its $6.7 billion acquisition of Arena Pharmaceuticals.
- Billie Inc. in the sale of its business to Edgewell Personal Care.
- Fitbit Inc. in its $2.1 billion sale to Google.
- Bristol-Myers Squibb in its $90 billion acquisition of Celgene and the related $13.4 billion divesture of Celgene's OTEZLA® program to Amgen.
- Kroger in its sale of YouTechnology, its digital coupon and digital rebate publishing unit, to Inmar.
- NxStage Medical Inc. in connection with its $2 billion sale to Fresenius Medical Care Holdings, Inc.
- AT&T Inc. in its successful $85.4 billion stock-and-cash acquisition of Time Warner Inc. After a DOJ investigation and the first vertical merger trial/appeal in decades, the transaction was approved with no finding of liability.
- BP in its $10.5 billion acquisition of BHP's US shale oil and gas assets.
- BP in its $155 million acquisition of the upstream portion of Clean Energy's renewable natural gas business and establishment of a long term supply contract with Clean Energy to support the firm's continuing downstream renewable natural gas business.
- General Electric in its $85 million sale of the GE Dharmacon business to Horizon Discovery.
- General Electric in connection with the proposed sale of its appliances business to AB Electrolux, including the DOJ's litigation challenging the transaction.
- General Electric in connection with the $5.6 billion sale of its appliances business to Qingdao Haier Co., Ltd.
"Ones to Watch"—Litigation: Antitrust (2022–2023)
- JD, St. John's University School of Law, 2008
- AB, Colby College, 2003, cum laude
- District of Columbia
- New York
- US District Court, District of Columbia
- US District Court, Eastern District of Michigan
- Counsel to the Director, Bureau of Competition, Federal Trade Commission
- International Exchange Competition Law Officer, Mergers Branch, Competition Bureau, Canada
- Attorney, Mergers IV, Bureau of Competition, Federal Trade Commission
- Fellow, American Bar Foundation
- Member, ABA Section of Antitrust Law
- Vice-Chair, ABA Section of Antitrust Law Media & Technology Committee (2021–2024)
- Associate Editor, ABA Section of Antitrust Law Media & Technology Committee’s e-Bulletin
Young Lawyer Representative, Agriculture & Food Committee, ABA Section of Antitrust Law (2014–2015)